659 related articles for article (PubMed ID: 18030330)
1. Subclass mapping: identifying common subtypes in independent disease data sets.
Hoshida Y; Brunet JP; Tamayo P; Golub TR; Mesirov JP
PLoS One; 2007 Nov; 2(11):e1195. PubMed ID: 18030330
[TBL] [Abstract][Full Text] [Related]
2. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
3. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
4. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
5. Unsupervised feature construction and knowledge extraction from genome-wide assays of breast cancer with denoising autoencoders.
Tan J; Ung M; Cheng C; Greene CS
Pac Symp Biocomput; 2015; 20():132-43. PubMed ID: 25592575
[TBL] [Abstract][Full Text] [Related]
6. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
Yu K; Ganesan K; Miller LD; Tan P
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
[TBL] [Abstract][Full Text] [Related]
7. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
8. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
Monti S; Savage KJ; Kutok JL; Feuerhake F; Kurtin P; Mihm M; Wu B; Pasqualucci L; Neuberg D; Aguiar RC; Dal Cin P; Ladd C; Pinkus GS; Salles G; Harris NL; Dalla-Favera R; Habermann TM; Aster JC; Golub TR; Shipp MA
Blood; 2005 Mar; 105(5):1851-61. PubMed ID: 15550490
[TBL] [Abstract][Full Text] [Related]
10. Inference of patient-specific subpathway activities reveals a functional signature associated with the prognosis of patients with breast cancer.
Han J; Liu S; Jiang Y; Xu C; Zheng B; Jiang M; Yang H; Su F; Li C; Zhang Y
J Cell Mol Med; 2018 Sep; 22(9):4304-4316. PubMed ID: 29971923
[TBL] [Abstract][Full Text] [Related]
11. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
12. Spectral gene set enrichment (SGSE).
Frost HR; Li Z; Moore JH
BMC Bioinformatics; 2015 Mar; 16():70. PubMed ID: 25879888
[TBL] [Abstract][Full Text] [Related]
13. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Rosenwald A; Wright G; Chan WC; Connors JM; Campo E; Fisher RI; Gascoyne RD; Muller-Hermelink HK; Smeland EB; Giltnane JM; Hurt EM; Zhao H; Averett L; Yang L; Wilson WH; Jaffe ES; Simon R; Klausner RD; Powell J; Duffey PL; Longo DL; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Montserrat E; López-Guillermo A; Grogan TM; Miller TP; LeBlanc M; Ott G; Kvaloy S; Delabie J; Holte H; Krajci P; Stokke T; Staudt LM;
N Engl J Med; 2002 Jun; 346(25):1937-47. PubMed ID: 12075054
[TBL] [Abstract][Full Text] [Related]
14. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
[TBL] [Abstract][Full Text] [Related]
15. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
[TBL] [Abstract][Full Text] [Related]
16. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
17. How different are luminal A and basal breast cancers?
Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Buttarelli M; Jacquemier J; Chaffanet M; Maraninchi D; Viens P; Birnbaum D
Int J Cancer; 2009 Mar; 124(6):1338-48. PubMed ID: 19058218
[TBL] [Abstract][Full Text] [Related]
18. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of a 92-probe signature in breast cancer.
Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]